A single-center, double-blind, randomised, placebo-controlled parallel-group study. Selected subjects will be randomised into active and control groups in a ratio of 1:1. Investigational products assigned will be applied on the facial skin as part of daily skin care routine. The effects will be observed during the 12-weeks of use.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
5
Apply on the face twice a day
School of Pharmaceutical Sciences, Universiti Sains Malaysia
Pulau Pinang, Malaysia
Proportion of participants with at least 50% reduction in numbers of acne lesion or at least 2 grade improvement according to CASS from baseline
Acne lesion count
Time frame: 18 Week
The percent change from baseline in global face total lesion count.
Acne lesion count
Time frame: 18 Week
Acne lesion counts for the total global face and total lesion counts
Acne lesion count
Time frame: 18 Week
CASS assessment
Comprehensive Acne Severity Scale (CASS)
Time frame: 18 Week
Survey (CADI)
The Cardiff Acne Disability Index 2021
Time frame: 18 Week
The percent change from baseline in sebum, skin pH, hydration and erythema index
Skin probe
Time frame: 18 Week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.